PT - JOURNAL ARTICLE AU - Keiichi Tsukinoki AU - Tetsuro Yamamoto AU - Jiro Saito AU - Wakako Sakaguchi AU - Keiichiro Iguchi AU - Yoshinori Inoue AU - Shigeru Ishii AU - Chikatoshi Sato AU - Mina Yokoyama AU - Yuki Shiraishi AU - Noriaki Kato AU - Hiroyasu Shimada AU - Akio Makabe AU - Akihiro Saito AU - Kiminori Tanji AU - Isao Nagaoka AU - Juri Saruta AU - Tetsutaro Yamaguchi AU - Shigenari Kimoto AU - Hideyo Yamaguchi TI - Prevalence of Salivary IgA Reacting with SARS-CoV-2 among Japanese People Unexposed to the Virus AID - 10.1101/2022.01.09.22268986 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.09.22268986 4099 - http://medrxiv.org/content/early/2022/01/10/2022.01.09.22268986.short 4100 - http://medrxiv.org/content/early/2022/01/10/2022.01.09.22268986.full AB - While the COVID-19 pandemic caused by SARS-CoV-2 has posed a threat to public health as the number of cases and COVID-19-related deaths are increasing worldwide, the incidence of the virus infection are extremely low in Japan compared with many other countries. To explore the reason for this strange phenomenon, we hypothesized the high prevalence of “natural” secretory IgA in saliva as mucosal IgA reacting with SARS-CoV-2, and thus surveyed the positivity for, as well as levels of, such reactive salivary IgA in a cohort of Japanese people of a wide range of age. The major findings were that 95/180 (52.78 %) of overall individuals who had not been exposed to SARS-CoV-2 were positive for salivary IgA with the levels ranging from 0.002 to 3.272 ng/ml, and that there may be a negative trend in positivity for salivary IgA according to age. These results suggest a role of mucosal IgA in host defense against SARS-CoV-2 infection.One Sentence Summary “Natural” secretory immunoglobulin A autoantibodies may play a role in mucosal defense against SARS-CoV-2.Competing Interest StatementAs employees of EPS, the following people are paid by EPS; T. Yamamoto, Y. Shiraishi, N. Kato, H. Shimada, A. Makabe, A. Saito, K. Tanji. Other authors declare no conflict of interest.Clinical Protocols https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000049910 Funding StatementKeiichi Tsukinoki was supported for this work by the EPS Holdings Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval to undertake the study was obtained from the Kanagawa Dental University Research Ethics Review Board (approval number: 792) on April 6, 2021. The study adhered to all the guidelines set forth in the Declaration of Helsinki (amended in October 2013), the Ethical Guidelines for Medical Research in Humans (noticed by the Ministry of Health, Labor and Welfare, the Japanese Government, in December 2014 [amended in February 2017]) and the Guidance of the Ethical Guidelines for Medical Research in Humans (enacted by the Ministry of Education and Science and the Ministry of Health, Labor and Welfare, the Japanese Government, in February 2015 [amended in March 2017]). Written informed consent was obtained from all participants themselves or informed assent from their legal representatives, mostly parents (in the case of children or adolescent participants aged below 20 years), prior to the study onset. The study was registered on April 1, 2021 in the database of the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) that meets the JCMJE standards. The study ID was UMIN000043717.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with this study are present in the paper.